Pfizer Analyst Price Targets - Benzinga

SPY778.57+0.60%QQQ751.38+0.51%BTC/USD83,757.13+1.01%DIA516.21+0.89%GLD384.50+1.55%TLT77.97+0.12%

Pfizer Inc

PFENYSE

Trade with Public

Trade with Public

$28.27

0.451.62%

Last update: Oct 9, 7:59 PM

$28.27

0.451.61%

Overview News Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Dividends Compare Options Stock Report

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell

© 2026 Benzinga | All Rights Reserved

Pfizer Analyst Price Targets - Benzinga

Pfizer Analyst Price Targets

Wall Street analyst price targets and consensus rating for Pfizer (PFE).

Price Target Range — 13 Quarters

Analyst Consensus — 19 Analysts

7Buy

10Hold

2Sell

Consensus RatingNeutral# Analysts19Avg. Consensus PT$30Upside to Avg. PT+6.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 9, 2026	JP Morgan	Chris Schott	PT Raise	Neutral	$28→$30
Oct 8, 2026	Cantor Fitzgerald	Carter Gould	PT Raise	Neutral	$27→$28
Oct 6, 2026	Scotiabank	Louise Chen	PT Raise	Sector Outperform	$30→$33
Sep 10, 2026	HSBC	Rajesh Kumar	PT Raise	Hold	$28→$30
Aug 7, 2026	Guggenheim	Vamil Divan	PT Cut	Buy	$35→$31
Jul 13, 2026	BMO Capital	Evan David Seigerman	PT Cut	Outperform	$34→$30
Jul 13, 2026	Guggenheim	Vamil Divan	PT Cut	Buy	$36→$35
Jul 10, 2026	B of A Securities	Jason Gerberry	PT Cut	Neutral	$27→$26
Jul 8, 2026	JP Morgan	Chris Schott	PT Cut	Neutral	$30→$28
Jul 6, 2026	Cantor Fitzgerald	Carter Gould	Maintained	Neutral	$27
Jul 6, 2026	HSBC	Rajesh Kumar	Downgrade	Buy→Hold	$32→$28
Jun 10, 2026	RBC Capital	Trung Huynh	Upgrade	Underperform→Sector Perform	$25
Apr 29, 2026	Citigroup	Geoff Meacham	PT Raise	Neutral	$26→$27
Apr 20, 2026	RBC Capital	Trung Huynh	Maintained	Underperform	$25
Apr 16, 2026	CICC	Jin Zhang	Initiate	Outperform	$33
Apr 13, 2026	UBS	Michael Yee	PT Raise	Neutral	$25→$27
Apr 10, 2026	Morgan Stanley	Terence Flynn	PT Raise	Equal-Weight	$27→$28
Apr 9, 2026	B of A Securities	Jason Gerberry	PT Cut	Neutral	$27→$26
Mar 24, 2026	Guggenheim	Vamil Divan	PT Raise	Buy	$35→$36
Mar 17, 2026	HSBC	Rajesh Kumar	PT Raise	Buy	$29→$32

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
JP Morgan Maintains Neutral on Pfizer, Raises Price Target to $30

JP Morgan analyst Chris Schott maintains Pfizer (NYSE:PFE) with a Neutral and raises the price target from $28 to $30.

Benzinga Newsdesk

PRO
Cantor Fitzgerald Maintains Neutral on Pfizer, Raises Price Target to $28

Cantor Fitzgerald analyst Carter Gould maintains Pfizer (NYSE:PFE) with a Neutral and raises the price target from $27 to $28.

Benzinga Newsdesk

PRO
HSBC Maintains Hold on Pfizer, Raises Price Target to $30

HSBC analyst Rajesh Kumar maintains Pfizer (NYSE:PFE) with a Hold and raises the price target from $28 to $30.

Benzinga Newsdesk

PRO
CNBC Halftime Report Final Trades: Pfizer, Nvidia, Take-Two Interactive Software, Cheniere Energy

Benzinga Newsdesk

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields

Benzinga readers can review the latest analyst takes on high-yielding stocks in health care sector. Top analysts & recent news on PRGO, PFE, BMY.

Avi Kapoor

PRO
Guggenheim Maintains Buy on Pfizer, Lowers Price Target to $31

Guggenheim analyst Vamil Divan maintains Pfizer (NYSE:PFE) with a Buy and lowers the price target from $35 to $31.

Benzinga Newsdesk